WALTHAM, Mass., Sept. 20 /PRNewswire/ -- Compound Therapeutics, Inc., a privately held biotechnology company, today announced the appointment of Katrine Bosley as Vice President, Business Development. Ms. Bosley brings more than fourteen years of experience in the biotechnology sector to this role. She will lead all business development activities related to Compound Therapeutics' three core technologies and growing product pipeline with the goal to establish collaborations, licenses, and product partnerships.
"Katrine brings a wealth of skills and experience to her new role at Compound Therapeutics. She has completed deals with both large and small companies and for both technology platforms and products, including leading Biogen's deal with Elan for Antegren(TM)," said Frank Lee, President and Chief Executive Officer of Compound Therapeutics. "Katrine's strong business development experience and leadership will be particularly important now that we have transitioned from purely drug discovery to a product development company."
Prior to joining Compound Therapeutics, Katrine spent more than eight years at Biogen Idec, Inc. where she led or developed a number of key functions. These included roles based in the U.S. and in Europe in business development, as well as in commercial operations and investor relations. In addition, she held positions with Highland Capital Partners, a venture capital firm, and Alkermes, a drug delivery company.
"Compound Therapeutics has a seasoned leadership team, and it's a privilege to be part of it. The company's technologies are very compelling -- they're the basis for a new generation of protein antagonist products that offer significant advantages over current antibody-based products. This company can both improve upon existing therapeutics and also take full advantage of the ever-increasing list of new biologic targets," said Katrine S. Bosley, Compound Therapeutics' new Vice President, Business Development. "There is tremendous potential for us to build a significant company through partnerships and the development of our own products."
About Compound Therapeutics
Compound Therapeutics is a privately held biotechnology company developing the next generation of protein antagonist therapeutics. The company has two proprietary product platforms that it applies to a wide range of biological targets; AdNectins(TM) are non-antibody based, highly specific binding proteins, and AdZymes(TM) are novel catalytic protein antagonists. Both platforms offer significant commercial and technical advantages over current technologies, including faster and lower-cost product development, improved product potency and specificity, as well as a strong intellectual property position that includes broad freedom to operate. Compound uses its unique protein display technology, PROfusion(TM), as a powerful tool to generate AdNectins, AdZymes, and other types of protein antagonists. The company is funded by three leading venture capital firms: Atlas Venture, Flagship Ventures, and Polaris Venture Partners.
Compound Therapeutics, Inc.